STRYKER CORP
SYKAPI behind this page
SYK Q1 2026 request
Playground key active
/api/financials?ticker=SYK&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 6,020 | 5,866 | +2.6% |
Show Product Lines breakouts |
|||
| Enabling Technologies | 26 | 29 | -10.3% |
| Endoscopy · MedSurg and Neurotechnology: | 701 | 710 | -1.3% |
| Endoscopy · MedSurg and Neurotechnology: | 167 | 157 | +6.4% |
| Endoscopy · MedSurg and Neurotechnology: | 868 | 867 | +0.1% |
| Hips · Orthopaedics: | 276 | 269 | +2.6% |
| Hips · Orthopaedics: | 184 | 174 | +5.7% |
| Hips · Orthopaedics: | 460 | 443 | +3.8% |
| Instruments · MedSurg and Neurotechnology: | 766 | 702 | +9.1% |
| Instruments · MedSurg and Neurotechnology: | 154 | 136 | +13.2% |
| Instruments · MedSurg and Neurotechnology: | 920 | 838 | +9.8% |
| Knees · Orthopaedics: | 472 | 464 | +1.7% |
| Knees · Orthopaedics: | 198 | 175 | +13.1% |
| Knees · Orthopaedics: | 670 | 639 | +4.9% |
| Medical · MedSurg and Neurotechnology: | 747 | 802 | -6.9% |
| Medical · MedSurg and Neurotechnology: | 155 | 143 | +8.4% |
| Medical · MedSurg and Neurotechnology: | 902 | 945 | -4.6% |
| Neuro Cranial Instruments | 606 | 563 | +7.6% |
| Ortho Tech · Orthopaedics: | 467 | 459 | +1.7% |
| Ortho Tech · Orthopaedics: | 179 | 158 | +13.3% |
| Ortho Tech · Orthopaedics: | 646 | 617 | +4.7% |
| Orthopaedic Instruments | 489 | 484 | +1.0% |
| Other Orthopedics | 157 | 133 | +18.0% |
| Spinal Implants · Orthopaedics: | 2 | 48 | -95.8% |
| Spinal Implants · Orthopaedics: | 2 | 166 | -98.8% |
| Trauma and Extremities · Orthopaedics: | 767 | 713 | +7.6% |
| Trauma and Extremities · Orthopaedics: | 268 | 232 | +15.5% |
| Trauma and Extremities · Orthopaedics: | 1,035 | 945 | +9.5% |
| Vascular · MedSurg and Neurotechnology: | 280 | 203 | +37.9% |
| Vascular · MedSurg and Neurotechnology: | 237 | 203 | +16.7% |
| Vascular · MedSurg and Neurotechnology: | 517 | 406 | +27.3% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: | 3,207 | 3,056 | +4.9% |
| MedSurg and Neurotechnology: · Non Us | 713 | 639 | +11.6% |
| MedSurg and Neurotechnology: · Operating Segments | 3,207 | 3,056 | +4.9% |
| MedSurg and Neurotechnology: · US | 2,494 | 2,417 | +3.2% |
| Orthopaedics · Operating Segments | 2,813 | 2,810 | +0.1% |
| Orthopaedics: | 2,813 | 2,810 | +0.1% |
| Orthopaedics: · Non Us | 831 | 787 | +5.6% |
| Orthopaedics: · US | 1,982 | 2,023 | -2.0% |
Show Geography breakouts |
|||
| Non Us | 1,544 | 1,426 | +8.3% |
| US | 4,476 | 4,440 | +0.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 6,020 | 5,866 | +2.6% |
| Cost of Revenue | 2,210 | 2,122 | +4.1% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 1,291 | 1,175 | +9.9% |
| Orthopaedics · Operating Segments | 823 | 775 | +6.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -13 | -2 | -550.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,114 | 1,950 | +8.4% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -13 | -2 | -550.0% |
| Gross Profit | 3,810 | 3,744 | +1.8% |
| Research & Development | 413 | 405 | +2.0% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 231 | 208 | +11.1% |
| Orthopaedics · Operating Segments | 146 | 158 | -7.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 377 | 366 | +3.0% |
| Selling, General & Administrative | 2,281 | 2,300 | -0.8% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 930 | 859 | +8.3% |
| Orthopaedics · Operating Segments | 880 | 925 | -4.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,810 | 1,784 | +1.5% |
| Amortization Of Intangible Assets | 180 | 167 | +7.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 180 | 167 | +7.8% |
| Operating Expenses | 2,874 | 2,907 | -1.1% |
| Operating Income | 936 | 837 | +11.8% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 700 | 757 | -7.5% |
| Orthopaedics · Operating Segments | 846 | 854 | -0.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,546 | 1,611 | -4.0% |
| Interest Expense | -148 | -137 | -8.0% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 1 | — | — |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | 1 | — | — |
| Non-Operating Income (Expense) | 62 | 64 | -3.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | — | — |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -10 | -11 | +9.1% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -11 | -11 | 0.0% |
| Income Before Taxes | 850 | 764 | +11.3% |
| Income Tax Expense (Benefit) | 105 | 110 | -4.5% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -2 | -1 | -100.0% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -2 | -3 | +33.3% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -4 | -4 | 0.0% |
| Net Income | 745 | 654 | +13.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 745 | 654 | +13.9% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 936 | 837 | +11.8% |
| EPS (Basic) | 1.95 | 1.71 | +14.0% |
| EPS (Diluted) | 1.93 | 1.69 | +14.2% |
| Wtd Avg Shares (Basic) | 382.9 | 381.7 | +0.3% |
| Weighted Average Number Diluted Shares Outstanding Adjustment | 3.6 | 4.7 | -23.4% |
| Wtd Avg Shares (Diluted) | 386.5 | 386.4 | 0.0% |
| Common Stock Dividends Per Share Declared | 0.88 | 0.84 | +4.8% |
| Comprehensive Income | 849 | 538 | +57.8% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract | 22 | 26 | -15.4% |
| Foreign Exchange Contract · Cost Of Sales | 13 | 2 | +550.0% |
| Foreign Exchange Contract · Other Nonoperating Income Expense | -1 | 13 | -107.7% |
Show Derivative Instruments Gain Loss By Hedging Relationship breakouts |
|||
| Net Investment Hedging · Other Nonoperating Income Expense | 10 | 11 | -9.1% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,878 | 2,320 | +24.1% |
| Available For Sale Securities Debt Securities Current | 87 | 89 | -2.2% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 87 | 89 | -2.2% |
| Fair Value Inputs Level2 · Asset Backed Securities | 48 | 58 | -17.2% |
| Fair Value Inputs Level2 · US Treasury Securities | 39 | 27 | +44.4% |
| Accounts Receivable | 3,571 | 3,961 | -9.8% |
| Inventory Raw Materials And Supplies Net Of Reserves | 1,473 | 1,196 | +23.2% |
| Inventory Work In Process Net Of Reserves | 435 | 398 | +9.3% |
| Inventory Finished Goods Net Of Reserves | 3,511 | 3,511 | 0.0% |
| Inventory | 5,419 | 5,105 | +6.2% |
| Prepaid Expense Current | 1,383 | 1,547 | -10.6% |
| Total Current Assets | 13,338 | 13,022 | +2.4% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,887 | 3,536 | +9.9% |
| Goodwill | 19,188 | — | — |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: | 11,945 | — | — |
| Orthopaedics | 7,243 | — | — |
| Deferred Tax Assets | 1,193 | 1,411 | -15.5% |
| Other Non-Current Assets | 3,169 | 2,816 | +12.5% |
| Total Assets | 46,291 | 46,006 | +0.6% |
| Operating Lease Right-of-Use Assets | 529 | 570 | -7.2% |
| Other Assets | |||
| Property Plant And Equipment Gross | 7,630 | 6,910 | +10.4% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 3,743 | 3,374 | +10.9% |
| Intangible Assets Net Excluding Goodwill | 5,516 | 6,132 | -10.0% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,592 | 1,464 | +8.7% |
| Employee Related Liabilities Current | 885 | 919 | -3.7% |
| Accrued Income Taxes Current | 476 | 599 | -20.5% |
| Dividends Payable Current | 337 | 320 | +5.3% |
| Other Liabilities Current | 2,526 | 2,229 | +13.3% |
| Debt Current | 499 | 2,398 | -79.2% |
| Total Current Liabilities | 6,315 | 7,929 | -20.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 14,224 | 14,383 | -1.1% |
| Accrued Income Taxes Noncurrent | 403 | 372 | +8.3% |
| Other Non-Current Liabilities | 2,370 | 2,392 | -0.9% |
| Total Liabilities | 23,312 | 25,076 | -7.0% |
| Operating Lease Liabilities | 350 | 414 | -15.5% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 38 | 38 | 0.0% |
| Additional Paid In Capital Common Stock | 2,646 | 2,439 | +8.5% |
| Retained Earnings | 20,878 | 18,862 | +10.7% |
| Accumulated Other Comprehensive Income | -583 | -409 | -42.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 22,979 | 20,930 | +9.8% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 69 | 4 | +1625.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 24 | 17 | +41.2% |
| Accumulated Other Comprehensive Income | -583 | -409 | -42.5% |
| Accumulated Translation Adjustment | -676 | -430 | -57.2% |
| Additional Paid In Capital | 2,646 | 2,439 | +8.5% |
| Common Stock | 38 | 38 | 0.0% |
| Retained Earnings | 20,878 | 18,862 | +10.7% |
| Total Liabilities & Equity | 46,291 | 46,006 | +0.6% |
| Land Buildings And Improvements Gross | 1,795 | 1,669 | +7.5% |
| Machinery And Equipment Gross | 5,835 | 5,241 | +11.3% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 120 | 105 | +14.3% |
| Stock-Based Compensation | 87 | 84 | +3.6% |
| Deferred Income Taxes | -33 | 14 | -335.7% |
| Change in Accounts Receivable | 444 | 144 | +208.3% |
| Change in Inventory | -127 | -93 | -36.6% |
| Increase Decrease In Accounts Payable Trade | -198 | -309 | +35.9% |
| Increase Decrease In Accrued Liabilities | -654 | -504 | -29.8% |
| Increase Decrease In Accrued Income Taxes Payable | 42 | 49 | -14.3% |
| Increase Decrease In Other Operating Capital Net | -25 | -130 | +80.8% |
| Net Cash from Operations | 581 | 250 | +132.4% |
| Depreciation & Amortization | 397 | 361 | +10.0% |
Show Business Segments breakouts |
|||
| MedSurg and Neurotechnology: · Operating Segments | 55 | 48 | +14.6% |
| Orthopaedics · Operating Segments | 119 | 107 | +11.2% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 43 | 39 | +10.3% |
| Operating Segments | 174 | 155 | +12.3% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | -22 | -4,749 | +99.5% |
| Payments To Acquire Marketable Securities | -5 | -11 | +54.5% |
| Proceeds From Sale And Maturity Of Marketable Securities | 7 | 17 | -58.8% |
| Capital Expenditures | -166 | -123 | -35.0% |
| Other Investing Activities | 1 | -20 | +105.0% |
| Net Cash from Investing | -185 | -4,136 | +95.5% |
| Financing Activities | |||
| Repayments Of Long Term Debt | -1,000 | — | — |
| Payments Of Dividends | -337 | -320 | -5.3% |
| Tax Withholding for Share Compensation | -139 | -101 | -37.6% |
| Proceeds From Payments For Other Financing Activities | -34 | -24 | -41.7% |
| Net Cash from Financing | -1,510 | 2,534 | -159.6% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -19 | 20 | -195.0% |
| Net Change in Cash | -1,133 | -1,332 | +14.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,878 | 2,320 | +24.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.